David Jones - Biography#

David Jones is internationally recognised for his research concerning the application of biomaterials science/engineering to address the industrial and clinical issues associated with implants and pharmaceutical dosage forms, including:

(i) Biomaterials to inhibit life-threatening problems associated with medical devices (e.g. ocular devices (co-developed with CibaVision) and a spin-out company Xiomateria (urological devices))

(ii) Tissue adherent implants with engineered drug-elution rates. Commercialisation includes treatments for infection in farmed animals (Provita-Eurotech) and the development of novel stoma sealants (Eakin).

(iii) Polymer extrusion technologies to improve drug release/provide targeted and multiple drug delivery options. These have influenced manufacture/dosage form design and resulted in a spin-out company, Eutectyx, in which Jones is a co-founder/CSO).

(iv) Biodegradable ocular implants providing controlled drug delivery to treat sight-threatening diseases and resulting in a spin-out company (Re-Vana; Jones is a co-founder and was Chief Scientific Advisor).

Jones has been elected to 3 national academies (Royal Academy of Engineering, Academy of Medical Sciences, Royal Irish Academy) and holds several Fellowships, e.g. the Irish Academy of Engineering, IoMMM, Royal Soc. of Chemistry, Royal Statistical Soc., and an Eminent Fellowship of the Acad. of Pharmaceutical Sciences (APS).

He has received 7 international research awards: (a) British Pharmaceutical Conference Science Medal Award, (b) Lilly Prize for Pharmaceutical Excellence, (c) APS Innovation Award (d) Griffith Medal of IoMMM (e) APS Award Lecture and (f) Chapman Medal of IoMMM (g) The Hanbury Medal of the Royal Pharmaceutical Society, Awarded for High excellence in the prosecution or promotion of original research in the Natural History and Chemistry of Drugs and he recently received a Member of the Order of the British Empire (MBE) for services to Pharmacy and Education.

His research has enhanced the sales of companies (>£25M), increased employment (25 staff) and allowed companies to expand their businesses.

Jones has an exceptional publication record including several patents. His H-index and number of citations are outstanding for an engineer (H=68, circa 19k citations, Google Scholar). His research has resulted in 21 commercialised products, whilst employed in academia. Noteworthy is the award-winning viscoelastic device (Cohesive Paste™), developed to improve stoma health and patients’quality of life.